HER2 Support Group Forums - View Single Post - Taxotere and JMR-132

heblaj01 · 02-19-2007, 09:21 PM

Thanks Eric for this post which covers the new JMR-132 drug. It is likely to be developed past mice experiments since "Tulane University has applied for a patent on the GHRH antagonist JMR-132" . This makes it attractive to potential licencees among pharmaceutical companies.

I am not sure about the stated inocuity of the Docetaxel dosage since in mice experiments they used it intraperitonally while in humans it is given as an I.V.
I don't know how to correlate the dose of 20mg/kg in mice with the 75 to 100mg per square meter in humans.
However the 10 µg/day (sub cutanous) looks very small & hopefully less toxic in humans than Docetaxel.

02-19-2007, 09:21 PM	#2
heblaj01 Senior Member Join Date: Apr 2006 Posts: 543	Thanks Eric for this post which covers the new JMR-132 drug. It is likely to be developed past mice experiments since "Tulane University has applied for a patent on the GHRH antagonist JMR-132" . This makes it attractive to potential licencees among pharmaceutical companies. I am not sure about the stated inocuity of the Docetaxel dosage since in mice experiments they used it intraperitonally while in humans it is given as an I.V. I don't know how to correlate the dose of 20mg/kg in mice with the 75 to 100mg per square meter in humans. However the 10 µg/day (sub cutanous) looks very small & hopefully less toxic in humans than Docetaxel.